China’s Sinovac Biotech defended the safety and efficacy of the company’s experimental Covid-19 vaccine, after researchers in Brazil released late-stage clinical data showing efficacy that was much lower than initially announced.

Worldwide coronavirus cases surpassed 90 million on Jan. 11, according to a Reuters tally, as nations around the globe scramble to procure vaccines and continue to extend or reinstate lockdowns to fight new coronavirus variants.

China approved a Covid-19 vaccine developed by an affiliate of state-backed pharmaceutical giant Sinopharm on Dec. 31, the country’s first approved shot for general public use as it braces for increased transmission risks over winter.

Myovant Sciences’ stock rocketed on news that the company was partnering with Pfizer to develop and commercialize Orgovyx (relugolix) for prostate cancer and women’s health.

Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.

Global coronavirus infections surpassed the 75 million mark on Dec. 19, according to a Reuters tally, as several nations around the world begin vaccinating against the virus.

Vaccine maker Novavax Inc. pushed back the start of a U.S.-based, late-stage trial for the company’s experimental Covid-19 vaccine.

The global tally of confirmed coronavirus cases hit 60 million on Nov. 25, with the pace of new infections accelerating and the United States reporting record numbers of hospitalizations, according to a Reuters tally.

Global coronavirus infections exceeded 50 million, according to a Reuters tally, with a second wave of the virus in the past 30 days accounting for a quarter of the total.

Europe’s new Covid-19 cases doubled in five weeks, propelling the region across the bleak milestone of 10 million total infections, according to a Reuters tally.